[Clinical and biochemical evaluation of the administration of growth hormone].

Abstract

Ten children with isolated growth hormone deficiency were treated for 1 year with 0.5 UI/kg week with Somatrem (recombinant human growth hormone), given as intramuscular injections three times weekly. Before treatment the children had a chronological age of 7-12.4 years (mean 10.4 years), with a bone age at least 25% below the chronological age. There was no radiological evidence of an intra or suprasellar mass in any child, and no response to provocative growth hormone tests (with exercise or arginine-insulin injection). Informed written consent for treatment was obtained from the parents of each child. Clinical signs were registered every month; triiodothyronine, thyroxine, thyrotropine, glucose, urea, creatinine, blood cells count, and hemoglobine, glycosylated hemoglobine, glutamic-piruvic and glutamic-oxalacetic transaminases, alkaline phosphatase, anti-human growth hormone and, E. coli antibodies, insulin like growth factor 1, and bone age were assessed every 3 months. The mean height velocity was 0.27 +/- 0.1 cm/month before treatment, and increased throughout treatment to a value of 0.62 +/- 0.16 cm/month after 12 months. Within the first year eight of the 10 children had a height increase of 8.4 +/- 0.98 cm. The other two children showed no significant difference; one of them with a very low socioeconomic status, and the other developed typhoid fever. All of the children showed an advance in bone age, but none reached a bone age appropriate for their chronological age; without modifications in the laboratory parameters. Insulin like growth factor 1 increased in 9 children. Pain at the injection site was the only side effect reported.

• Authors: F Mendoza-Morfin, H Cárdenas-Tirado
• Journal: Boletin medico del Hospital Infantil de Mexico (Bol Med Hosp Infant Mex) Vol. 47 Issue 8 Pg. 551-6 (Aug 1990) ISSN: 0539-6115 [Print] Mexico
• Vernacular Title: Evaluación clínica y bioquímica de la administración de hormona de crecimiento.
• PMID: 2257092 (Publication Type: English Abstract, Journal Article)

Chemical References

• Recombinant Proteins
• Human Growth Hormone
• Growth Hormone

Topics

• Antibody Formation
• Child
• Female
• Growth Disorders (blood, drug therapy)
• Growth Hormone (analogs & derivatives, immunology, therapeutic use)
• Human Growth Hormone
• Humans
• Male
• Recombinant Proteins (immunology, therapeutic use)